复星医药与梯瓦达成战略合作 共同开发肿瘤免疫治疗新药抗PD1-IL2疗法(TEV-56278)

复星医药
16 Jun

由梯瓦研发的TEV-56278是一款抗PD1-IL2 ATTENUKINE™疗法,目前正处于I期临床试验阶段,开发适应症涵盖黑色素瘤等多种癌症;复星医药与梯瓦的战略合作,旨在加速TEV-56278的全球临床开发;此次战略伙伴将推动创新疗法研发,进一步夯实复星医药在肿瘤免疫治疗领域的布局。(2025年6月16日,中国上海,以色列特拉维夫)上海复星医药(集团)股份有限公司(“复星医药”,股票代码:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10